First Minimally Invasive Tricuspid Valve Replacement Performed in Mainz
A groundbreaking procedure has been performed at the University Medical Center Mainz, marking a significant advancement in the treatment of tricuspid regurgitation. Led by Univ.-Prof. Dr. Philipp Lurz, the director of cardiology, the team successfully conducted the first minimally invasive tricuspid valve replacement using the innovative Evoque technology.
Tricuspid regurgitation is a condition where the tricuspid valve, located between the right atrium and right ventricle, fails to prevent blood from flowing back into the right atrium. This valve, like the aortic valve, is 'tricuspid' in nature, featuring three cusps. The condition is common in diseased hearts, often due to drug abuse.
The procedure, performed by Prof. Lurz and his team, involved the use of the Evoque technology, a new approach to tricuspid valve replacement. The device was inserted via a catheter, allowing for a minimally invasive procedure. This method is expected to reduce recovery time and potential complications compared to traditional open-heart surgery.
The successful implementation of this new technology at the University Medical Center Mainz offers hope for improved treatment of tricuspid regurgitation. The minimally invasive procedure, led by Prof. Lurz, could pave the way for better outcomes and reduced risks for patients suffering from this condition.
Read also:
- Hospital's Enhancement of Outpatient Services Alleviates Emergency Department Strain
- Increased Chikungunya infections in UK travelers prompt mosquito bite caution
- Kazakhstan's Deputy Prime Minister holds discussions on the prevailing circumstances in Almaty
- In the state, Kaiser Permanente boasts the top-ranked health insurance program
